Skip to main content

Table 2 Risk of death from breast cancer in association with Menacalc

From: Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer

Combined Cohort 1 and 2 (n = 608; 231)*
Variable   cHR (95% CI) P-value
Age    
  <50 1.00 0.0738
  >50 1.316 (0.97 to 1.78)  
Tumor size   
  <2 cm 1.00 <0.0001
  2 to 5 cm 2.127 (1.57 to 2.88)  
Nuclear grade   
  low 1.00  
  high 1.250 (0.93 to 1.68) 0.0397
  ND 2.414 (1.10 to 5.32)  
Nodal status   
  Positive 2.161 (1.60 to 2.92) <0.0001
  Negative 1.00  
ER    
  Positive 0.755 (0.57 to 1.00) 0.0549
  Negative 1.00  
PR    
  Positive 0.899 (0.68 to 1.19) 0.4602
  Negative 1.00  
Her2    
  Positive 1.360 (0.96 to 1.93) 0.0834
  Negative 1.00  
Menacalc    
  1 to 3 Q 1.00  
  4 Q 1.597 (1.20 to 2.13) 0.0015
Menacalc continuous 1.211 (1.08 to 1.36) 0.0016
  1. The P-values are shown for a 20-year follow-up and bold numbers indicate statistically significant P-value.
  2. *The number of patients in each cohort is shown followed by the number of patient deaths due to disease.